Cystic Fibrosis

AAV6 Efficiently And Preferentially Transduces Airway Epithelium

Published in Gene Therapy Weekly, September 6th, 2001

by Deborah W. Heinrich, PhD, staff medical writer - Cystic fibrosis patients may breathe easier now that a more efficient vector has been identified for gene therapy of the airways.

In order for gene therapy to effectively treat cystic fibrosis, it is critical that airway epithelial cells are transduced with the therapeutic gene. Up to now, many researchers have been working with the adeno-associated virus type 2 (AAV2) vector. Difficulties lie in the fact that the apical surfaces of airway epithelial cells are highly resistant to AAV2 transfection. Attempts to improve transfection efficiency by increasing vector dose and "perturbing the integrity of the epithelium"...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-09-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry